CN116173056A - Application of nucleoside compound in preparation of medicine with anti-drunk and anti-alcohol effects - Google Patents
Application of nucleoside compound in preparation of medicine with anti-drunk and anti-alcohol effects Download PDFInfo
- Publication number
- CN116173056A CN116173056A CN202210322878.1A CN202210322878A CN116173056A CN 116173056 A CN116173056 A CN 116173056A CN 202210322878 A CN202210322878 A CN 202210322878A CN 116173056 A CN116173056 A CN 116173056A
- Authority
- CN
- China
- Prior art keywords
- group
- cytosine
- lamivudine
- alcohol
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention relates to the technical field of medicines, in particular to application of a nucleoside compound in preparation of medicines with anti-drunk and anti-alcohol functions, wherein the nucleoside compound is cytosine nucleoside, cytosine nucleotide and lamivudine. Experimental results show that the cytidine, the cytidine and the lamivudine can obviously prolong the time required by disappearance of the flip-flop and shorten the time required by recovery of the flip-flop, namely, the cytidine and the lamivudine have the effects of preventing drunkenness and accelerating sobering, and the novel application of the cytidine, the cytidine and the lamivudine is provided.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of nucleoside compounds in preparation of medicines with anti-drunk and anti-alcohol effects.
Background
In recent years, with the rapid development of economy and the improvement of living standard, alcohol consumption groups and consumption amount are increasing year by year, and alcohol abuse is becoming a global serious problem. According to world health organization statistics, about 330 tens of thousands of deaths are related to alcohol every year worldwide, accounting for 5.9% of all deaths annually. The drinking will make the emotion of the person easy to be excited, the judgment and control force lower, and the drinking will be more sensitive to the external stimulus, which will cause the drinker to easily conflict with other people, engage in dangerous crime, and implement violent behavior to spouse and children, and bring serious harm to society and family. The excessive drinking of the wine at one time can lead to the unconsciousness of the drinker, and the drinker can not wake or act without being controlled in a short time, so that the safety of the drinker can not be ensured, and the drinker is more likely to die due to alcoholism. At present, the main anti-alcoholic drugs independently developed in China are mainly compositions, for example, patent (CN 102038867B) discloses an anti-alcoholic composition, which comprises the following raw materials: s-adenomethionine or cysteine or mixture of more than two of methionine, D-glyceric acid or D-glycerate, succinic acid or fumaric acid or citric acid or oxaloacetic acid or malic acid or mixture of more than two, vitamin B1 or vitamin B6 or vitamin B2 or mixture of more than two, coenzyme Q10 or coenzyme I or mixture, L-glutamine, herba Eupatorii, herba Artemisiae Scopariae, radix Paeoniae alba and fructus crataegi. Patent (CN 106492110B) also discloses an anti-alcoholic composition comprising the following components: maca extract, kudzu root extract, turmeric extract and hovenia dulcis extract. However, no single-component anti-hangover drugs have been developed.
Cytosine nucleoside is one of pyrimidine nucleosides constituting nucleic acid, is composed of cytosine and ribose, is an essential compound constituting life, is an important intermediate for drug synthesis in modern medicine, and has no definite medical use in clinic. Cytosine nucleotide is one of pyrimidine nucleotides, and a constituent component of RNA has no definite medical application in clinic. Lamivudine is a nucleoside analogue with competitive inhibition of synthesis and elongation of viral DNA strand, and is mainly used for the treatment of hepatitis b and hepatobiliary diseases.
The inventor has unexpectedly found in the experimental process that the cytidine, the cytidine and the lamivudine have the functions of preventing alcohol intolerance, alcohol intoxication and accelerating sobering, and provide new application for the cytidine, the cytidine and the lamivudine.
Disclosure of Invention
Aiming at the problems, the invention provides application of a nucleoside compound in preparing a medicament for preventing and/or treating drunkenness and dispelling alcohol, wherein the nucleoside compound is cytosine nucleoside, cytosine nucleotide and lamivudine, the structural formula of the cytosine nucleoside is shown as a formula (I), the structural formula of the lamivudine is shown as a formula (II), and the structure of the cytosine nucleotide is shown as a formula (III):
the second object of the present invention is to provide an application of a nucleoside compound in preparing a medicament for treating and/or preventing alcoholism, alcohol death or alcohol complications, wherein the nucleoside compound is a cytosine nucleoside, a cytosine nucleotide or lamivudine, the structural formula of the cytosine nucleoside is shown as formula (I), the structural formula of the lamivudine is shown as formula (II), and the structure of the cytosine nucleotide is shown as formula (III):
the third object of the invention is to provide an application of a nucleoside compound in preparing a health care product with anti-drunk and anti-alcohol effects, wherein the nucleoside compound is cytosine nucleotide, and the structure of the cytosine nucleotide is shown as a formula (III):
preferably, the medicament is added with a pharmaceutically acceptable carrier to prepare powder, tablets, granules, capsules, solutions, emulsions, suspensions and injections.
Preferably, the medicine is added with a pharmaceutically acceptable carrier to prepare tablets and capsules.
Preferably, the medicine is taken sublingually or swallowed.
Preferably, the medicine with the effects of preventing drunk and dispelling alcohol is taken before and/or after drinking alcohol.
The beneficial effects of the invention are as follows: the invention provides a new application of a nucleoside compound in preparing a medicament with anti-drunk and anti-alcohol effects, wherein the nucleoside compound is cytosine nucleoside, cytosine nucleotide and lamivudine, and experimental results show that: (1) cytosine nucleosides have an effect of preventing drunk; the dose of the cytosine nucleoside group is 1/5 of the dose of the RU21 positive control group, that is, the cytosine nucleoside achieves the same effect of preventing drunk as the RU21 An Tipu composite sheet of the positive control group at a lower dose; (2) cytosine nucleosides have an anti-hangover effect; the dose of the cytosine nucleoside group is 1/5 of the dose of the RU21 positive control group, that is, the cytosine nucleoside achieves the same effect of accelerating sobering up as the RU21 An Tipu composite sheet of the positive control group at a lower dose; (3) cytosine nucleosides have an inhibitory effect on alcohol mortality; the dose of the cytosine nucleoside group was 1/5 of the dose of RU21 in the positive control group, that is, the cytosine nucleoside had the same effect of inhibiting alcohol death as the RU21 An Tipu composite sheet in the positive control group at a lower dose. (4) lamivudine has the effect of preventing drunk; the dosage of lamivudine in the lamivudine group is 1/25 of that of RU21 in the positive control group, that is, lamivudine achieves better effect of preventing drunk than that of RU21 An Tipu composite sheet in the positive control group at lower dosage; (5) lamivudine has the effect of accelerating sobering up; compared with a model group, the lamivudine group can obviously shorten the time required by recovery of the flip-flop of the mice, which shows that the lamivudine has the effect of accelerating sobering; meanwhile, the dosage of lamivudine in the lamivudine group is 1/25 of that of RU21 in the positive control group, that is, lamivudine in a lower dosage achieves better effect of accelerating sobering than that of RU21 An Tipu composite tablets in the positive control group. (6) lamivudine has an effect of inhibiting alcohol death; the dose of lamivudine in the positive control group was 1/25 of the dose of RU21, that is, lamivudine in the lower dose had the same effect of suppressing alcohol death as that of the positive control group RU21 An Tipu composite sheet. (7) cytosine nucleotides have an effect of preventing drunk; the administration dose of the cytosine nucleotide group is 100mg/kg lower than that of the positive medicine group RU21, that is, the cytosine nucleotide achieves the same drunk prevention effect as that of the positive control group RU21 at a lower administration dose; (8) cytosine nucleotides have the effect of accelerating sobering up; the dosage of the cytosine nucleotide group is 100mg/kg lower than that of the positive medicine group RU21, that is, the cytosine nucleotide achieves the same sober-up accelerating effect as that of the positive control group RU21 at a lower dosage; (9) Cytosine nucleotides have an effect of inhibiting alcohol death; the dose of cytosine nucleotide group was 100mg/kg lower than that of RU21 in the positive drug group, that is, cytosine nucleotide had the same effect of suppressing death as that of RU21 An Tipu composite sheet in the positive control group at a lower dose.
Drawings
FIG. 1 is a diagram showing the length of a column required for the disappearance of the everlasting reflection in mice of each administration group according to the present invention;
wherein "Control" is a blank Control group without alcohol intervention, "Model" is a Model Control group with one-time excessive alcohol intervention, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "cytodine" is a cytosine nucleoside group. Ns >0.05 compared to the positive control RU21 An Tipu compact.
FIG. 2 is a diagram showing the length of columns required for recovery from the everlasting reflex in mice of each administration group according to the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "Cytidine" is a cytosine nucleoside group. Ns >0.05 compared to the positive control RU21 An Tipu compact.
FIG. 3 is a bar graph showing mortality of mice in each of the dosing groups 24h after drinking according to the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "Cytidine" is a cytosine nucleoside group. There was no difference compared to the positive control RU21 An Tipu composite plate group.
FIG. 4 is a long bar graph showing the time required for the disappearance of the everlasting reflection in mice of each administration group according to the present invention;
wherein "Control" is a blank Control group without alcohol intervention, "Model" is a Model Control group with one-time excessive alcohol intervention, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "Lamivudine" is a Lamivudine group. P <0.001 compared to the disposable overdose alcohol intervention Model group "Model"; p <0.001 compared to the positive control RU21 An Tipu complex.
FIG. 5 is a bar graph showing the length of time required for recovery from orthostatic reflex in mice of each administration group according to the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "Lamivudine" is a Lamivudine group. P <0.001 compared to the disposable overdose alcohol intervention model group "Control"; p <0.05 compared to the positive control RU21 An Tipu panel. FIG. 6 is a bar graph of mortality of mice in each of the dosing groups 24h after drinking provided by the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "Lamivudine" is a cytosine nucleoside group. There was no difference compared to the positive control RU21 An Tipu composite plate group.
FIG. 7 is a long bar graph showing the time required for the disappearance of the everlasting reflection in mice of each administration group according to the present invention;
wherein "Control" is a blank Control group without alcohol intervention, "Model" is a Model Control group with one-time excessive alcohol intervention, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "5' -CMP" is a cytosine nucleotide group. Ns >0.05 compared to the positive control RU21 An Tipu panel.
FIG. 8 is a bar graph showing the length of time required for recovery from orthostatic reflex in mice of each administration group according to the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "5' -CMP" is a cytosine nucleotide group. Ns >0.05 compared to the positive control RU21 An Tipu panel.
FIG. 9 is a bar graph showing mortality of mice in each of the dosing groups 24h after drinking according to the present invention;
wherein "Control" is a group without alcohol intervention, "Model" is a Control group of a disposable excessive alcohol intervention Model, "RU21" is a positive Control RU21 An Tipu composite sheet group, and "5' -CMP" is a cytosine nucleotide group. There was no difference compared to the positive control RU21 An Tipu composite plate group.
Detailed Description
The technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings in the examples of the present invention, and it is apparent that the described examples are only some, but not all, examples of the present invention, and the therapeutic effects of cytosine nucleosides, cytosine nucleotides, and lamivudine on symptoms occurring after all alcohol interventions are protected, including different dosage forms, dosages, etc. All other embodiments, which can be made by one of ordinary skill in the art based on the embodiments of the present invention without the benefit of the inventive faculty, are intended to be within the scope of the present invention.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the inventive subject matter herein. In this application, it must be noted that, as used in this specification and the claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the use of "or" means "and/or" unless stated otherwise. Furthermore, the terms "include" and other forms, such as "comprising," "including," and "containing," are not limiting.
The RU21 An Tipu compact of the present invention is produced by us Spi r it Sciences and is now the best known anti-hangover product worldwide.
Example one, study of the effects of cytidine on preventing intoxication, accelerating sobering up and inhibiting alcohol death
1. Experimental animal
SPF-class male Kunming mice of 4 weeks of age were selected and all weighing 22+ -2 g. Provided by the state veterinary research institute of the national academy of agricultural sciences. No drug was used before the experiment. The experimental animals are adapted to be raised for one week in the environment with 24-26 ℃ and 12h/12h day rule alternation, and the animals are fed with diet and drink water freely, and then the experiments are carried out in groups.
2. Medicament and reagent
Cytosine nucleoside (Cytidine, HPLC. Gtoreq.99%), aladin Biotechnology Co., ltd., lot: c100358, molecular weight 243.22;
RU21 An Tipu composite sheet, purchased from Spirit Science USA, lot number: 25794;
absolute ethyl alcohol is adopted to prepare the water-free ethanol, purchased from the company, fuyu fine chemical Co., ltd., lot number: 11/8/2020.
3. Experimental grouping and intragastric administration dosage
36 male 4 week old Kunming mice were randomly assigned to a Control blank (Control), model Control (Model), positive Control (RU 21), and Cytidine (Cytidine) group, 4 groups of 9.
4. Experimental method
36 Kunming mice were grouped as described above, and after 12h of fasted prior to the experiment, the Control group (Control) and the Model group (Model) were perfused with equal volumes of physiological saline, the positive Control group (RU 21) was perfused with RU21 An Tipu complex at a dose of 500mg/kg, and the cytosine nucleoside group (Cytidine) was perfused with cytosine nucleoside at a dose of 100 mg/kg. 30min after the completion of the stomach filling, the other three groups are filled with 60% alcohol according to the dosage of 0.16mL/10g except for a blank group Control (Control) gastric filling equal volume double distilled water, the timing is immediately started, the length of time required for the positive reflection disappearance time of each group of mice to be turned over, the duration of time for the positive reflection recovery and the survival rate of each group of mice after 24h after drinking are recorded and calculated.
5. Experimental results
(1) Length of time required for disappearance of the eversion and the specular reflection of the mice
As shown in fig. 1, the mice in the model group required shorter time period for the disappearance of the anti-normal reflection compared with the blank control group, and the model group accords with the drunken model after one-time overdrinking, which indicates that the model construction is successful. The time effect required for the cytosine nucleoside to prolong the disappearance of the positive reflection of the mice compared with the positive control group was not significantly different from that of the positive control RU21 An Tipu composite sheet group (ns > 0.05), indicating that the cytosine nucleoside and the positive control RU21 An Tipu composite sheet have the same effect of preventing drunk, but in the present experiment, the administration dose of the positive control group was 500mg/kg, the administration dose of the cytosine nucleoside group was 100mg/kg, and the administration dose was 1/5 of that of the positive control group, that is, the cytosine nucleoside had the same effect of preventing drunk as the positive control RU21 An Tipu composite sheet at a lower administration dose.
(2) The length of time required for recovery of the normal reflex of the mice
As shown in fig. 2, the effect of the cytosine nucleoside for shortening the time period required for recovery of the eversion and the reflection of the mice was not significantly different from that of the positive control RU21 An Tipu composite sheet group (ns > 0.05), indicating that the cytosine nucleoside had the same effect of accelerating sober-up as the positive control RU21 An Tipu composite sheet, but in this experiment, the administration dose of the positive control group was 500mg/kg and the administration dose of the cytosine nucleoside group was 100mg/kg, and the administration dose was 1/5 of that of the positive control group, that is, the cytosine nucleoside had the same effect of accelerating sober-up as that of the positive control RU21 An Tipu composite sheet at a lower administration dose.
(3) Survival rate of mice in each group after 24 hours after drinking
As shown in FIG. 3, compared with the model group, cytosine nucleosides have an effect of inhibiting alcohol death within 24 hours after drinking; compared with the positive control group, the effect of the cytosine nucleoside on inhibiting alcohol death within 24 hours after drinking is not significantly different from that of the positive control RU21 An Tipu composite sheet (ns > 0.05), however, in the experiment, the administration dose of the positive control group is 500mg/kg, the administration dose of the cytosine nucleoside group is 100mg/kg, and the administration dose is 1/5 of that of the positive control group, that is, the cytosine nucleoside achieves the same effect of inhibiting alcohol death as that of the positive control RU21 An Tipu composite sheet at a lower administration dose. Example two, study of the effects of lamivudine in preventing drunkenness, accelerating sobering and inhibiting alcohol death
1. Experimental animal
SPF-class male Kunming mice of 4 weeks of age were selected and all weighing 22+ -2 g. Provided by the state veterinary research institute of the national academy of agricultural sciences. No drug was used before the experiment. The experimental animals are adapted to be raised for one week in the environment with 24-26 ℃ and 12h/12h day rule alternation, and the animals are fed with diet and drink water freely, and then the experiments are carried out in groups.
2. Medicament and reagent
Lamivudine (Lamivudine, HPLC ≡98%), purchased from microphone biotechnology limited, lot number: c10102050, molecular weight 229.25;
RU21 An Tipu composite sheet, purchased from Spirit Science USA, lot number: 25794;
absolute ethyl alcohol is adopted to prepare the water-free ethanol, purchased from the company, fuyu fine chemical Co., ltd., lot number: 11/8/2020.
3. Experimental grouping and intragastric administration dosage
36 male 4 week old Kunming mice were randomly assigned to a Control blank (Control), model Control (Model), positive Control (RU 21), lamivudine (Lamivudine) group, 4 groups of 9.
4. Experimental method
36 Kunming mice were grouped as described above, and after 12h of fasted prior to the experiment, the Control group (Control) and the Model group (Model) were perfused with equal volumes of physiological saline, the positive Control group (RU 21) was perfused with RU21 An Tipu composite tablets at a dose of 500mg/kg, and the Lamivudine group (Lamivudine) was perfused with Lamivudine at a dose of 20 mg/kg. 30min after the completion of the stomach filling, the other three groups are filled with 60% alcohol according to the dosage of 0.16mL/10g except for a blank group Control (Control) gastric filling equal volume double distilled water, and immediately begin timing, and the time for the loss of the positive reflection and the recovery of the positive reflection of each group of mice are recorded.
5. Experimental results
(1) Length of time required for disappearance of the eversion and the specular reflection of the mice
As shown in fig. 4, the mice in the model group required shorter time period for the disappearance of the anti-normal reflection compared with the blank control group, and the model group accords with the drunken model after one-time overdrinking, which indicates that the model construction is successful. Lamivudine group compared with model group, lamivudine can significantly prolong the time (p < 0.001) required for the disappearance of the mouse eversion and the positive reflection, which indicates that lamivudine has the effect of preventing drunk. Compared with a positive control RU21 An Tipu composite tablet group, the lamivudine group can significantly prolong the time (p < 0.001) required for the disappearance of the positive reflection of the turning of mice, and shows that the effect of the lamivudine on preventing drunk is better than that of the RU21 An Tipu composite tablet.
(2) The length of time required for recovery of the normal reflex of the mice
As shown in fig. 5, lamivudine can significantly shorten the time period required for recovery of the flip-flop of mice compared with the model group (p < 0.001), indicating that lamivudine has an effect of accelerating sober-up. Compared with a positive control RU21 An Tipu composite tablet group, the lamivudine can significantly shorten the time period required for recovery of the positive reflection of mice (p < 0.05), and shows that the effect of accelerating sobering up of the lamivudine is superior to that of the RU21 An Tipu composite tablet.
(3) Survival rate of mice in each group after 24 hours after drinking
As shown in fig. 6, lamivudine has an effect of suppressing alcohol death within 24 hours after drinking, compared with the model group; compared with the positive control RU21 An Tipu composite tablet group, the effect of lamivudine on inhibiting alcohol death within 24 hours after drinking is not significantly different from that of the RU21 An Tipu composite tablet (ns > 0.05).
Example III, study of effects of cytosine nucleotide on preventing drunkenness and accelerating sobering
1. Experimental animal
SPF-class male Kunming mice of 4 weeks of age were selected and all weighing 22+ -2 g. Provided by the state veterinary research institute of the national academy of agricultural sciences. No drug was used before the experiment. The experimental animals are adapted to be raised for one week in the environment with 24-26 ℃ and 12h/12h day rule alternation, and the animals are fed with diet and drink water freely, and then the experiments are carried out in groups.
2. Medicament and reagent
Cytosine nucleotide (Cytidine-5' -monophosphate, HPLC. Gtoreq.98%), purchased from Aladin Biotechnology Co., ltd., lot: j1831067, molecular weight 323.20;
RU21 An Tipu composite sheet, purchased from Spirit Science USA, lot number: 25794;
absolute ethyl alcohol is adopted to prepare the water-free ethanol, purchased from the company, fuyu fine chemical Co., ltd., lot number: 11/8/2020.
3. Experimental grouping and intragastric administration dosage
40 male 4 week old Kunming mice were randomly assigned to a Control blank (Control), model Control (Model), positive Control (RU 21), cytosine nucleotide (5' -CMP) group, 4 groups of 10 each.
4. Experimental method
40 Kunming mice were grouped as described above, and after 12h of fasted prior to the experiment, the Control group (Control) and the Model group (Model) were perfused with equal volumes of physiological saline, the positive Control group (RU 21) was perfused with RU21 An Tipu composite sheet at a dose of 500mg/kg, and the cytosine nucleotide group (5' -CMP) was perfused with cytosine nucleotides at a dose of 400 mg/kg. 30min after the completion of the stomach filling, the other three groups are filled with 60% alcohol according to the dosage of 0.16mL/10g except for a blank group Control (Control) gastric filling equal volume double distilled water, and immediately begin timing, and the time for the loss of the positive reflection and the recovery of the positive reflection of each group of mice are recorded.
5. Experimental results
(1) Length of time required for disappearance of the eversion and the specular reflection of the mice
As shown in fig. 7, the mice in the model group required shorter time period for the disappearance of the anti-normal reflection compared with the blank control group, and the model group accords with the drunken model after one-time overdrinking, which indicates that the model construction is successful. Compared with a model group, the cytosine nucleotide can obviously prolong the time required by the disappearance of the flip-flop of the mice, which indicates that the cytosine nucleotide has the function of preventing drunk; meanwhile, compared with the positive control group, the time required for the cytosine nucleotide to prolong the disappearance of the eversion and the specular reflection of the mice is longer, and there is no significant difference (ns > 0.05) among groups, but in the experiment, the administration dose of the positive control RU21 An Tipu composite sheet group is 500mg/kg, the administration dose of the cytosine nucleotide group is 400mg/kg, and the administration dose is 100mg/kg lower than that of the positive control RU21 An Tipu composite sheet group, that is, the cytosine nucleotide achieves the same drunk prevention effect as that of the positive control RU21 An Tipu composite sheet at a lower administration dose.
(2) The length of time required for recovery of the normal reflex of the mice
As shown in fig. 8, compared with the model group, the cytosine nucleotide group can shorten the time period required for recovery of the flip-flop of the mice, which indicates that the cytosine nucleotide has the effect of accelerating sober-up; compared with the positive control RU21 An Tipu composite sheet group, the time period required for shortening the recovery of the flip-flop of the mice by the cytosine nucleotide group has no significant difference (ns > 0.05), but in the experiment, the administration dose of the positive control RU21 An Tipu composite sheet group is 500mg/kg, the administration dose of the cytosine nucleotide group is 400mg/kg, and the administration dose is 100mg/kg lower than that of the positive control RU21 An Tipu composite sheet group, that is, the cytosine nucleotide achieves the same sober-up effect as that of the positive control RU21 An Tipu composite sheet at a lower administration dose.
(3) Survival rate of mice drunk
As shown in fig. 3, compared with the model group, the cytosine nucleotide group can inhibit death caused by excessive drinking of mice at one time, which indicates that the cytosine nucleotide has the effect of inhibiting death caused by excessive drinking; compared with the positive control group, the effect of inhibiting death caused by excessive drinking of mice at one time is the same, however, in the experiment, the administration dose of the positive control RU21 An Tipu composite sheet group is 500mg/kg, the administration dose of the cytosine nucleotide group is 400mg/kg, and the administration dose is 100mg/kg lower than that of the positive control RU21 An Tipu composite sheet group, that is, the effect of inhibiting death is the same as that of the positive control group RU21 An Tipu composite sheet at a lower administration dose of the cytosine nucleotide.
In conclusion, the invention evaluates the treatment effects of cytosine nucleoside, cytosine nucleotide and lamivudine on preventing drunk, accelerating sobering and inhibiting alcohol death by adopting a disposable excessive alcohol intake animal model, and proves that the cytosine nucleoside, cytosine nucleotide and lamivudine have the effects of preventing drunk, accelerating sobering and inhibiting alcohol death.
The technical solutions obtained by the technicians through logic analysis, inference and experiments in the prior art according to the thought of the invention all belong to the scope of protection in the claims.
Claims (7)
1. The application of the nucleoside compound in preparing a medicament for preventing and/or treating drunkenness and dispelling the effects of alcohol is characterized in that the nucleoside compound is cytosine nucleoside, cytosine nucleotide or lamivudine, the structural formula of the cytosine nucleoside is shown in a formula (I), the structural formula of the lamivudine is shown in a formula (II), and the structure of the cytosine nucleotide is shown in a formula (III):
2. the application of the nucleoside compound in preparing a medicament for treating and/or preventing alcoholism, alcohol death or alcohol complications is characterized in that the nucleoside compound is cytosine nucleoside, cytosine nucleotide or lamivudine, the structural formula of the cytosine nucleoside is shown in a formula (I), the structural formula of the lamivudine is shown in a formula (II), and the structure of the cytosine nucleotide is shown in a formula (III):
3. the application of the nucleoside compound in preparing a health care product with the effects of preventing drunk and dispelling alcohol is characterized in that the nucleoside compound is cytosine nucleotide, and the structure of the cytosine nucleotide is shown as a formula (III):
4. the use according to claim 1, wherein the medicament is formulated into powder, tablet, granule, capsule, solution, emulsion, suspension, injection by adding pharmaceutically acceptable carrier.
5. The use according to claim 4, wherein the medicament is formulated into tablets or capsules by adding a pharmaceutically acceptable carrier.
6. The use of claim 5, wherein the medicament is administered sublingually or swallowed.
7. The use according to claim 1, wherein the medicament having anti-intoxication and anti-hangover effects is administered before and/or after drinking.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111422980 | 2021-11-26 | ||
| CN2021114229800 | 2021-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116173056A true CN116173056A (en) | 2023-05-30 |
Family
ID=86447622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210322878.1A Pending CN116173056A (en) | 2021-11-26 | 2022-03-30 | Application of nucleoside compound in preparation of medicine with anti-drunk and anti-alcohol effects |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116173056A (en) |
-
2022
- 2022-03-30 CN CN202210322878.1A patent/CN116173056A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0256329B2 (en) | ||
| CN107951869A (en) | Pharmaceutical preparation and its application containing cannabidiol | |
| CN111991401A (en) | Application of compound in treatment of SARS-CoV-2 infection | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| Everett et al. | The pharmacology of medieval sedatives: The “Great Rest” of the Antidotarium nicolai | |
| CN106031725B (en) | The medicinal application of Nuciferine and its analog | |
| CN116173056A (en) | Application of nucleoside compound in preparation of medicine with anti-drunk and anti-alcohol effects | |
| CN116098918A (en) | Citicoline pharmaceutical composition and application thereof | |
| CN105168846A (en) | Oral composition with physiological function | |
| CN114732826A (en) | Application of gamma-aminobutyric acid and spinosyn in prevention, alleviation or treatment of anxiety | |
| CN106928298A (en) | The structure composition of ring dinucleotides cGAMP derivatives, preparation method and its application in antitumor | |
| CN111558045A (en) | Medicine composition for treating lung cancer | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN104435109A (en) | Method for preparing Houtongling granule composition | |
| TWI272947B (en) | Pharmaceutical compositions for suppressing influenza virus infection and replication | |
| Arıca et al. | Convulsion in infants as a result of oral use of garden sage | |
| CN114751914B (en) | Sesquiterpene derivative and application thereof in preparation of broad-spectrum antiviral drugs | |
| CN112353837B (en) | Flos puerariae extract and its use | |
| WO2022217481A1 (en) | Application of nucleoside analogues in preparation of drugs for preventing and/or treating cerebrovascular diseases | |
| CN115120677B (en) | Traditional Chinese medicine composition for tonifying kidney and soothing nerves and preparation method thereof | |
| CN111450109B (en) | Application of cyclic adenosine monophosphate and derivatives thereof in resisting EV71 virus | |
| CN102389564A (en) | Compositions for use in treating myelodysplastic syndrome | |
| CN117338772B (en) | Pharmaceutical composition and application thereof in preparation of drugs for preventing and/or treating major depressive disorder | |
| CN113827603B (en) | Application of adefovir in preparing medicine for treating glioma | |
| CN117899099A (en) | Application of swertiamarin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |